Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
The MiniMax M2.7 AI model has undergone extensive testing and emerged as a standout option in the competitive AI landscape. According to World of AI, this model not only surpasses the performance of ...
AMD’s Ryzen AI Max+ 395 Strix Halo processor packs a lot of power into a mobile chip designed for laptops and mini PCs. With integrated graphics that rivals a discrete GPU, it offers an efficient ...
XDA Developers on MSN
I tested Claude's two biggest competitors because of its usage limits, and one banned my account
I don't really know why, though.
Dubbed “mini-maxes” – after infamous adult Goulburn “Supermax” jail – the units will replace smaller existing units deemed no longer fit for purpose, with under-siege staff hoping it will help keep ...
SHANGHAI: Two Chinese artificial intelligence (AI) startups seen as possible rivals to OpenAI aim to complete their Hong Kong initial public offerings (IPOs) in the coming weeks. Shanghai-based ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results